Drugs / TEP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03417986 | Nov 2017 → Jul 2021 | Alzheimer disease | Immungenetics AG | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03417986 ↗ |
| Action | Inhibit | “Thiethylperazine, a dopamine receptor antagonist with antiemetic and antidopaminergic properties, has been proposed as a potential therapeutic agent for AD.” PMID 41218709 ↗ Nov 2025 |